yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
granupas (previously para-aminosalicylic acid lucane)
eurocept international b. v. - para-aminosalicylic syre - tuberkulose - antimykobakterielle - granupas angis for bruk som en del av en passende kombinasjon diett for multi-resistente tuberkulose i voksne og pediatriske pasienter fra 28 dager alder og eldre når en effektiv behandling diett kan ellers ikke består av motstand eller toleranse (se seksjon 4. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.
truscient
zoetis belgium sa - dibotermin alfa - benmorfogenetiske proteiner - hunder - osteoinductive agent for bruk i behandling av lang-benbrudd som et tillegg til standard kirurgisk behandling ved hjelp av åpne brudd reduksjon i hunder.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
insulin human winthrop
sanofi-aventis deutschland gmbh - insulin human - sukkersyke - legemidler som brukes i diabetes - diabetes mellitus hvor behandling med insulin er nødvendig. insulin human winthrop rapid er også egnet for behandling av hyperglykemisk koma og ketoacidose, samt for å oppnå pre-, intra- og postoperativ stabilisering hos pasienter med diabetes mellitus.
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiske midler - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multippelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
episalvan
amryt ag - betulae cortex - wounds and injuries; wound healing - preparater for behandling av sår og sår - behandling av partikelsårssår hos voksne. se avsnitt 4. 4 og 5. 1 i produktinformasjon med hensyn til undersøkt type sår.
tasigna
novartis europharm limited - nilotinib - leukemi, myelogen, kronisk, bcr-abl positiv - antineoplastiske midler - tasigna er angitt for behandling av:voksne og paediatric pasienter med nylig diagnostisert philadelphia kromosom positiv kronisk myelogen leukemi (cml) i den kroniske fasen,paediatric pasienter med philadelphia kromosom positiv kml i kronisk fase med resistens eller intoleranse overfor tidligere behandling inkludert imatinib. tasigna er angitt for behandling av:voksne og paediatric pasienter med nylig diagnostisert philadelphia kromosom positiv kronisk myelogen leukemi (cml) i den kroniske fasen,voksne pasienter med kronisk fase og akselerert fase philadelphia kromosom positive cml med resistens eller intoleranse overfor tidligere behandling inkludert imatinib. effekten av data hos pasienter med kml i blast-krisen er ikke tilgjengelig,paediatric pasienter med kronisk fase philadelphia kromosom positive cml med resistens eller intoleranse overfor tidligere behandling inkludert imatinib.